Media Articles Related to Covera-HS (Verapamil)
Could a common blood pressure drug completely reverse diabetes?
Source: Pharma Industry / Biotech Industry News From Medical News Today [2014.11.06]
Verapamil, a common blood pressure drug, has been shown to completely reverse diabetes in mice. Now, researchers are conducting a clinical trial to see if it works in humans.
Published Studies Related to Covera-HS (Verapamil)
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
BACKGROUND: beta-blockers and calcium channel blockers are highly effective medications indicated for treatment and prevention of hypertension. However, the literature regarding the potential depressive effects of beta-blockers and calcium channel blockers is equivocal regarding whether one or both are associated with depression. OBJECTIVES: To determine whether self-reported depressive symptoms of older persons with hypertension and coronary artery disease and who were randomly assigned to a verapamil-sustained-release-led (Ve-led) or atenolol-led (At-led) hypertension treatment strategy were similar using confirmatory factor analytical models of the Center for Epidemiologic Studies Depression Scale (CES-D)... CONCLUSIONS: The domains indicating less happiness and more depressive symptoms were most likely to be unfavorably impacted by the At-led treatment strategy. Given a choice between these equally effective high blood pressure treatment strategies, it may be prudent to use the Ve-led strategy. This is especially true if the risk of the occurrence of a mood-related side effect of the beta-blocker outweighs its other benefits in comparison. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. [2011.08]
Microdosing studies are effective in enabling the early identification of the pharmacokinetic properties of compounds administered to humans. However, the nonlinearity of the pharmacokinetics between microdose and therapeutic dose, attributable to the saturation of metabolic enzymes and transporters, is a major concern.
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]
The purpose of this study was to evaluate the effects of antihypertensive drugs on renal hemodynamics in hypertensive patients during an adrenergic activation by mental stress (MS), which induces renal vasoconstriction in healthy subjects. Renal hemodynamics was assessed twice in 30 middle-aged essential hypertensive patients (57+/-6 years)-after 15 days of pharmacological wash-out and after 15 days of treatment with Trandolapril (T, 4 mg, n=10), Verapamil (V, 240 mg, n=10), or both (T 2 mg+V 180 mg, n=10)...
The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. [2011.06]
OBJECTIVE: Verapamil and adenosine are the most common agents used to treat paroxysmal supraventricular tachycardia (PSVT). We performed a systematic review and meta-analysis to determine the relative effectiveness of these drugs and to examine their respective adverse effect profiles... CONCLUSION: Adenosine and verapamil have similar efficacy in treating PSVT. Adenosine has a higher rate of minor adverse effects, and of overall adverse effects, whereas verapamil has a higher rate of causing hypotension. A decision between the two agents should be made on a case-by-case basis and ideally involve informed discussion with the patient where appropriate.
A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. [2011.02.01]
BACKGROUND AND OBJECTIVE: In microdose studies, the pharmacokinetic profile of a drug in blood after administration of a dose up to 100 mug is measured with sensitive analytical techniques, such as accelerator mass spectrometry (AMS)... Conclusion: Combining AMS and PET microdosing allows long-term pharmacokinetic data along with information on drug tissue distribution to be acquired in the same subjects thus making it a promising approach to maximize data output from a single clinical study.
Clinical Trials Related to Covera-HS (Verapamil)
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers [Recruiting]
The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug
interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome [Recruiting]
This study will assess how well the drug verapamil can improve control of seizures and
dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The
safety of verapamil when given with all concomitant medications will also be assessed.
Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness [Recruiting]
Chronic dizziness and recurrent vertigo are frequent complaints in primary and specialty
medical care settings. Two common causes of these symptoms are vestibular migraine (VM) and
chronic subjective dizziness (CSD), which may be seen in up to 25% of patients examined in
tertiary neurotology centers. However, VM and CSD are relatively new diagnoses that have
not yet been validated. Furthermore, recent research found that they co-exist 30% of the
time with overlap in several features. From a clinical standpoint, this makes it difficult
to diagnose and treat them well. From a research standpoint, it confounds subject selection
for mechanistic investigations.
The primary goal of this study to dissect VM and CSD in order to identify the key features
and clarify the diagnostic criteria of each condition. Fifty patients diagnosed with
coexisting VM-CSD will be treated with either verapamil or sertraline. Based on clinical
and research experience to date, verapamil is thought to have greater effect on
migraine-related symptoms, whereas sertraline is thought to have greater effect on
CSD-related symptoms. It is hypothesized that a differential treatment response to these
two pharmacologic probes will help to tease apart the unique clinical features of VM and CSD
and identify risk factors that are shared or separate between the two conditions. The
different mechanisms of action of the two study medications may also shed light on the
physiologic underpinnings of VM and CSD.
This project will be a 14-week, prospective, randomized, double-blind, parallel group,
pharmacologic dissection trial. A 12-week treatment period will follow 2 weeks of baseline
observation. Patients will chart daily headache and vestibular symptoms. VM and CSD
symptoms and potential confounds such as anxiety and depression will be measured at two week
intervals. Data will be analyzed for differential and shared treatment effects that align
with or oppose current concepts of VM and CSD.
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]
We, the researchers at the Indiana University School of Medicine, are doing this study to
better understand how the effects of certain medications are altered when taken
simultaneously, or in combination with each other. We will also look at how each volunteer's
genes (DNA) may affect the way these medications are metabolized.
We will test the hypothesis that the extent of drug-drug interaction caused by the
combination of erythromycin and diltiazem is not predictable from the extent of interaction
produced by each inhibitor alone. Specifically we will test the hypothesis that the
combination of erythromycin and diltiazem will cause a greater decrease in midazolam
intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.
Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee [Recruiting]
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the
safety, tolerability, and efficacy of Intra-Articular (IA) verapamil in the treatment of
joint pain in patients with knee osteoarthritis (OA). Subjects will discontinue all
analgesic medications for the entire duration of the study, except for acetaminophen (taken
on an as needed basis at no more than 2 g/day). At visit 2, subjects who meet all entry
criteria will be randomized to receive a single injection of IA verapamil or IA placebo at a
ratio of 1: 1. Treatments will be given with fluoroscopy or ultrasound to confirm needle
placement. Subjects will be monitored for blood pressure and heart rate (sitting and
standing) for at least 1 hour post-injection. Subjects will be evaluated at weeks 1, 2, 3,
4, 6, 8, and 12 after treatment.
Reports of Suspected Covera-HS (Verapamil) Side Effects
Joint Swelling (4),
Myocardial Infarction (2),
Angina Pectoris (2),
Intentional Overdose (1),
Completed Suicide (1),
Blood Pressure Inadequately Controlled (1),
Blood Cholesterol Increased (1), more >>